Genmab (0MGB)
London Stock Exchange · UK · prices in DKK · close of 27 Oct 2026
Key indicators
| Last close | DKK 3,002.00 |
|---|---|
| 52-week range | 1,514.50 – 3,002.00 |
| Return, 1 month / 3 months | +32.1% / +58.9% |
| Return, 1 year / 3 years | +58.3% / +47.9% |
| Trend | Uptrend |
| RSI (14) | 84 |
| Volatility (1 year) | 35.3% |
| Worst drawdown (1 year) | -32.3% |
| Average daily value traded | 29.54M DKK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Genmab is a biotechnology company based in Copenhagen, Denmark, that develops antibody-based medicines for the treatment of cancer and other serious diseases. Its work centres on engineered antibodies designed to help the immune system attack cancer cells, and it advances these candidates through clinical development. The company works with pharmaceutical partners on late-stage programmes and also markets some of its medicines itself, serving patients through oncology treatment centres and specialist physicians.
The shares are listed on the London Stock Exchange in UK under the code 0MGB, and the price on this page is in Danish kroner (DKK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Genmab (0MGB) trades on the London Stock Exchange in UK. It last closed at DKK 3,002.00 on 27 October 2026.
Its price-based Market X-Ray is 78 out of 100 (a strong price profile), ranking 137 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 58.3% and over the last three months it rose 58.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 96 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 54.7% | ||
| From 52-week high | 0.0% | ||
| Momentum | 88 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 58.9% | ||
| 6-month return | 75.9% | ||
| 12-month return, skipping the last month | 19.8% | ||
| Stability (higher is calmer) | 47 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 35.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -32.3% | ||
| Liquidity | 81 · Strong | Trades actively. | |
| Average daily value traded | 29.54M DKK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +15.9% |
|---|---|
| 1 month | +32.1% |
| 3 months | +58.9% |
| 6 months | +75.9% |
| 1 year | +58.3% |
| 3 years | +47.9% |
| 5 years | +2.6% |
Signals
| 50-day / 200-day average | 2,326.54 / 1,940.67 |
|---|---|
| Golden / death cross (60 days) | Golden, 46 days ago |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 101.35 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.